Replies to post #198957 on Biotech Values

[biomaven0]

A screening-oriented blood test for cancer will quite possibly prove to be a nightmare. It very likely will not tell you where the cancer is located - just that it exists. It will also likely not detect highly localized tumors given they are thought not to produce circulating tumor cells.

So it is at least plausible that such a test will greatly increase worry, scans, surgery and chemo without having a dramatic impact on outcomes.

Liquid testing for tumors being treated can only be good though. Being able to detect mutations without biopsies will be a significant step forwards.

Peter

[DewDiligence]

ILMN -20%/AH on soft 1Q16 results:

http://finance.yahoo.com/news/illumina-announces-preliminary-revenue-first-200500774.html

“Our first quarter results fell short of expectations largely due to lower than expected sales of HiSeq 2500, 3000 and 4000 instruments. Despite this slow start in Q1, we anticipate that our Americas and Asia Pacific regions will meet our expectations for the full year, but that Europe will underperform. As a result, we now project approximately 12% revenue growth for fiscal 2016,” stated Jay Flatley, Chairman and CEO.

[biocqr]

ILMN, Grrail, Helix >Illumina, Secret Giant Of DNA Sequencing, Is Bringing Its Tech To The Masses

https://www.fastcompany.com/3061591/body-os/illumina-owns-the-dna-sequencing-market-now-its-building-an-app-store-too